The new data presented by Novartis at ECTRIMS 2022 highlighted the safety and efficacy of Kesimpta and supported its use as an early intervention treatment option, as well as demonstrating high ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

NVS has approved drugs like Kesimpta and Zolgensma in its portfolio. Novartis has entered into ... While Olema maintains global commercial and marketing rights to palazestrant, all clinical ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods. Novartis announced ... the At the Veeva Commercial Summit in Madrid ...

Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...

We expect leading efficacy from multiple sclerosis drug Kesimpta, and cancer drugs Kisqali and Pluvicto will support significant growth for these top Novartis drugs. We expect additional growth ...

Kesimpta, Kisqali, Cosentyx and Leqvio. The top line beat the Zacks Consensus Estimate of $12.97 billion. Shares are up in response to the quarterly results. Shares of Novartis have risen 1.3% in ...

Novartis’ performance in the fourth quarter was impressive, driven by strong growth in Entresto, Kesimpta and Kisqali. The guidance for 2025 was encouraging, indicating strong momentum across ...